ID=wsj_1542.1 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT The NP[nb]_174/N_174>) (<T N 1 2> (<L N NNP NNP Food N>) (<T N[conj] 1 2> (<L conj CC CC and conj>) (<T N 1 2> (<L N/N NNP NNP Drug N_165/N_165>) (<L N NNP NNP Administration N>) ) ) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/S[dcl] VBD VBD said (S[dcl]\NP_8)/S[dcl]_9>) (<T S[dcl] 1 2> (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP American N_155/N_155>) (<T N 1 2> (<L N/N NNP NNP Home N_148/N_148>) (<T N 1 2> (<L N/N NNP NNP Products N_141/N_141>) (<L N NNP NNP Corp. N>) ) ) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/(S[to]\NP) VBD VBD agreed (S[dcl]\NP_18)/(S[to]_19\NP_18:B)_19>) (<T S[to]\NP 0 2> (<L (S[to]\NP)/(S[b]\NP) TO TO to (S[to]\NP_28)/(S[b]_29\NP_28:B)_29>) (<T S[b]\NP 0 2> (<L (S[b]\NP)/NP VB VB recall (S[b]\NP_36)/NP_37>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N JJ JJ certain N_53/N_53>) (<T N 1 2> (<L N/N JJ JJ generic N_46/N_46>) (<L N NNS NNS drugs N>) ) ) ) (<T NP\NP 0 2> (<L (NP\NP)/(S[dcl]\NP) WDT WDT that (NP_64\NP_64)/(S[dcl]_65\NP_64:B)_65>) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/(S[pss]\NP) VBD VBD were (S[dcl]\NP_74)/(S[pss]_75\NP_74:B)_75>) (<T S[pss]\NP 0 2> (<L S[pss]\NP VBN VBN produced S[pss]\NP_80>) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN by ((S_93\NP_88)_93\(S_93\NP_88)_93)/NP_94>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N PRP$ PRP$ its NP[nb]_115/N_115>) (<T N 1 2> (<L N/N NNP NNP Quantum N_110/N_110>) (<T N 1 2> (<L N/N NNP NNP Pharmics N_103/N_103>) (<L N NN NN unit N>) ) ) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN in (NP_123\NP_123)/NP_124>) (<T NP 0 2> (<T NP 0 1> (<L N NNP NNP Amityville N>) ) (<T NP[conj] 1 2> (<L , , , , ,>) (<T NP 0 1> (<L N NNP NNP N.Y N>) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_1542.2 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 0 1> (<L N NNP NNP Quantum N>) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/(S[ng]\NP) VBD VBD stopped (S[dcl]\NP_161)/(S[ng]_162\NP_161:B)_162>) (<T S[ng]\NP 0 2> (<T S[ng]\NP 0 2> (<T S[ng]\NP 0 2> (<T S[ng]\NP 0 2> (<L (S[ng]\NP)/NP VBG VBG shipping (S[ng]\NP_169)/NP_170>) (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_177/N_177>) (<L N NNS NNS drugs N>) ) ) (<T (S\NP)\(S\NP) 1 2> (<L ((S\NP)\(S\NP))/((S\NP)\(S\NP)) JJ JJ last ((S_212\NP_204)_212\(S_205\NP_204)_205)_212/((S_212\NP_204)_212\(S_205\NP_204)_205)_212>) (<L (S\NP)\(S\NP) NN NN month (S_189\NP_184)_189\(S_189\NP_184)_189>) ) ) (<L , , , , ,>) ) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP VBG VBG following ((S_227\NP_222)_227\(S_227\NP_222)_227)/NP_228>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT a NP[nb]_242/N_242>) (<T N 1 2> (<L N/N JJ JJ federal N_237/N_237>) (<L N NN NN investigation N>) ) ) (<T NP\NP 0 1> (<T S[ng]\NP 0 2> (<L (S[ng]\NP)/NP VBG VBG regarding (S[ng]\NP_249)/NP_250>) (<T NP 0 2> (<T NP 0 1> (<L N NN NN information N>) ) (<T NP\NP 0 1> (<T S[dcl]/NP 1 2> (<T S/(S\NP) 0 1> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_313/N_313>) (<L N NN NN company N>) ) ) (<T (S[dcl]\NP)/NP 0 2> (<L (S[dcl]\NP)/NP VBD VBD supplied (S[dcl]\NP_260)/NP_261>) (<T (S\NP)\(S\NP) 0 1> (<T S[to]\NP 0 2> (<L (S[to]\NP)/(S[b]\NP) TO TO to (S[to]\NP_270)/(S[b]_271\NP_270:B)_271>) (<T S[b]\NP 0 2> (<L (S[b]\NP)/NP VB VB obtain (S[b]\NP_278)/NP_279>) (<T NP 0 1> (<T N 1 2> (<L N/N CD CD three N_295/N_295>) (<T N 1 2> (<L N/N NN NN drug N_288/N_288>) (<L N NNS NNS approvals N>) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_1542.3 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT The NP[nb]_481/N_481>) (<L N NNP NNP FDA N>) ) (<T S[dcl]\NP 0 2> (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/NP VBD VBD requested (S[dcl]\NP_145)/NP_146>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_153/N_153>) (<L N NN NN recall N>) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN of (NP_161\NP_161)/NP_162>) (<T NP 1 2> (<T NP[nb]/N 1 2> (<T NP 0 1> (<L N NNP NNP Quantum N>) ) (<L (NP[nb]/N)\NP POS POS 's (NP[nb]_224/N_224)\NP_225>) ) (<T N 1 2> (<L N/N NN NN mioxidil N_217/N_217>) (<T N 1 2> (<L N/N NNS NNS tablets N_210/N_210>) (<T N 1 2> (<L , , , , ,>) (<T N 1 2> (<L N/N NN NN chlorazepate N_201/N_201>) (<T N 1 2> (<L N/N NN NN dipotassium N_194/N_194>) (<T N 1 2> (<L N/N NNS NNS tablets N_187/N_187>) (<T N 1 2> (<L conj CC CC and conj>) (<T N 1 2> (<L N/N NN NN meclofenamate N_178/N_178>) (<T N 1 2> (<L N/N NN NN sodium N_171/N_171>) (<L N NNS NNS capsules N>) ) ) ) ) ) ) ) ) ) ) ) ) ) (<T (S\NP)\(S\NP) 0 2> (<T ((S\NP)\(S\NP))/S[dcl] 0 2> (<L ((S\NP)\(S\NP))/S[dcl] IN IN because ((S_241\NP_236)_241\(S_241\NP_236)_241)/S[dcl]_242>) (<T ((S\NP)\(S\NP))\((S\NP)\(S\NP)) 1 2> (<L , , , , ,>) (<T ((S\NP)\(S\NP))\((S\NP)\(S\NP)) 0 2> (<T S[dcl]/S[dcl] 1 2> (<T S/(S\NP) 0 1> (<L NP PRP PRP it NP>) ) (<L (S[dcl]\NP)/S[dcl] VBD VBD said (S[dcl]\NP_249)/S[dcl]_250>) ) (<L , , , , ,>) ) ) ) (<T S[dcl] 1 2> (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_386/N_386>) (<L N NN NN size N>) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN of (NP_394\NP_394)/NP_395>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_409/N_409>) (<T N 1 2> (<L N/N NN NN production N_404/N_404>) (<L N NNS NNS runs N>) ) ) (<T NP\NP 0 1> (<T S[pss]\NP 0 2> (<T S[pss]\NP 0 2> (<L S[pss]\NP VBN VBN submitted S[pss]\NP_414>) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN for ((S_427\NP_422)_427\(S_427\NP_422)_427)/NP_428>) (<T NP 0 1> (<L N NN NN testing N>) ) ) ) (<T (S\NP)\(S\NP) 0 1> (<T S[to]\NP 0 2> (<L (S[to]\NP)/(S[b]\NP) TO TO to (S[to]\NP_440)/(S[b]_441\NP_440:B)_441>) (<T S[b]\NP 0 2> (<L (S[b]\NP)/NP VB VB gain (S[b]\NP_448)/NP_449>) (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP FDA N_458/N_458>) (<L N NN NN approval N>) ) ) ) ) ) ) ) ) ) ) (<T S[dcl]\NP 0 2> (<T (S[dcl]\NP)/(S[pss]\NP) 0 2> (<L (S[dcl]\NP)/(S[pss]\NP) VBD VBD was (S[dcl]\NP_292)/(S[pss]_293\NP_292:B)_293>) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN in ((S_306\NP_301)_306\(S_306\NP_301)_306)/NP_307>) (<T NP 1 2> (<L NP[nb]/N DT DT each NP[nb]_314/N_314>) (<L N NN NN case N>) ) ) ) (<T S[pss]\NP 0 2> (<L (S[pss]\NP)/PP VBN VBD misrepresented (S[pss]\NP_321)/PP_322>) (<T PP 0 2> (<L PP/(S[adj]\NP) IN IN as PP/(S[adj]_329\NP_327)_329>) (<T S[adj]\NP 0 2> (<T S[adj]\NP 1 2> (<L (S[adj]\NP)/(S[adj]\NP) RB RB much (S[adj]_346\NP_341)_346/(S[adj]_346\NP_341)_346>) (<L S[adj]\NP JJR JJR larger S[adj]\NP_334>) ) (<T (S[adj]\NP)\(S[adj]\NP) 0 2> (<L ((S[adj]\NP)\(S[adj]\NP))/S[dcl] IN IN than ((S[adj]_359\NP_354)_359\(S[adj]_359\NP_354)_359)/S[dcl]_360>) (<T S[dcl] 1 2> (<L NP PRP PRP it NP>) (<T S[dcl]\NP 1 2> (<L (S\NP)/(S\NP) RB RB actually (S_377\NP_372)_377/(S_377\NP_372)_377>) (<L S[dcl]\NP VBD VBD was S[dcl]\NP_365>) ) ) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_1542.4 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 0 2> (<T NP 0 2> (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP American N_444/N_444>) (<T N 1 2> (<L N/N NNP NNP Home N_437/N_437>) (<L N NNP NNP Products N>) ) ) ) (<L , , , , ,>) ) (<T NP\NP 0 1> (<T S[pss]\NP 0 2> (<L S[pss]\NP VBN VBN based S[pss]\NP_452>) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN in ((S_465\NP_460)_465\(S_465\NP_460)_465)/NP_466>) (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP New N_475/N_475>) (<L N NNP NNP York N>) ) ) ) ) ) ) (<L , , , , ,>) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/(S[to]\NP) VBD VBD agreed (S[dcl]\NP_273)/(S[to]_274\NP_273:B)_274>) (<T S[to]\NP 0 2> (<L (S[to]\NP)/(S[b]\NP) TO TO to (S[to]\NP_283)/(S[b]_284\NP_283:B)_284>) (<T S[b]\NP 0 2> (<T S[b]\NP 0 2> (<T S[b]\NP 0 2> (<L (S[b]\NP)/NP VB VB recall (S[b]\NP_291)/NP_292>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N/N CD CD four N_308/N_308>) (<T N 1 2> (<L N/N JJ JJ other N_301/N_301>) (<L N NNS NNS products N>) ) ) ) (<T NP[conj] 1 2> (<L , , , , ,>) (<T NP 0 1> (<T N 1 2> (<L N NN NN trazadone N>) (<T N[conj] 1 2> (<L , , , , ,>) (<T N 1 2> (<L N NN NN doxepin N>) (<T N[conj] 1 2> (<L , , , , ,>) (<T N 1 2> (<L N NN NN diazepam N>) (<T N[conj] 1 2> (<L conj CC CC and conj>) (<L N NN NN lorazapam N>) ) ) ) ) ) ) ) ) ) ) (<L , , , , ,>) ) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/PP IN IN because ((S_341\NP_336)_341\(S_341\NP_336)_341)/PP_342>) (<T PP 0 2> (<L PP/NP IN IN of PP/NP_347>) (<T NP 0 2> (<T NP 0 1> (<L N NNS NNS concerns N>) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN about (NP_358\NP_358)/NP_359>) (<T NP 0 2> (<T NP 0 1> (<L N NNS NNS data N>) ) (<T NP\NP 0 1> (<T S[pss]\NP 0 2> (<T S[pss]\NP 0 2> (<L S[pss]\NP VBN VBN submitted S[pss]\NP_367>) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN in ((S_380\NP_375)_380\(S_380\NP_375)_380)/NP_381>) (<T NP 1 2> (<L NP[nb]/N PRP$ PRP$ their NP[nb]_402/N_402>) (<T N 1 2> (<L N/N JJ JJ original N_397/N_397>) (<T N 1 2> (<L N/N NN NN approval N_390/N_390>) (<L N NNS NNS applications N>) ) ) ) ) ) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN before ((S_415\NP_410)_415\(S_415\NP_410)_415)/NP_416>) (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_423/N_423>) (<L N NNP NNP FDA N>) ) ) ) ) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_1542.5 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T S[dcl] 1 2> (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT No NP[nb]_214/N_214>) (<T N 1 2> (<L N/N NN NN safety N_209/N_209>) (<L N NNS NNS problems N>) ) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN with (NP_222\NP_222)/NP_223>) (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_230/N_230>) (<L N NNS NNS products N>) ) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/(S[pss]\NP) VBP VBP are (S[dcl]\NP_194)/(S[pss]_195\NP_194:B)_195>) (<L S[pss]\NP VBN VBN known S[pss]\NP_200>) ) ) (<T S[dcl]\S[dcl] 1 2> (<L , , , , ,>) (<T S[dcl]\S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_183/N_183>) (<L N NNP NNP FDA N>) ) (<L (S[dcl]\S[dcl])\NP VBD VBD said (S[dcl]\S[dcl]_175)\NP_176>) ) ) ) (<L . . . . .>) ) 
ID=wsj_1542.6 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT An NP[nb]_142/N_142>) (<T N 1 2> (<L N/N NNP NNP FDA N_137/N_137>) (<L N NN NN spokesperson N>) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/S[dcl] VBD VBD said (S[dcl]\NP_62)/S[dcl]_63>) (<T S[dcl] 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_128/N_128>) (<L N NNS NNS drugs N>) ) (<T S[dcl]\NP 0 2> (<T S[dcl]\NP 0 2> (<T (S[dcl]\NP)/(S[adj]\NP) 0 2> (<L (S[dcl]\NP)/(S[adj]\NP) VBP VBP are (S[dcl]\NP_72)/(S[adj]_73\NP_72:B)_73>) (<L (S\NP)\(S\NP) RB RB still (S_85\NP_80)_85\(S_85\NP_80)_85>) ) (<L S[adj]\NP JJ JJ available S[adj]\NP_90>) ) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN under ((S_103\NP_98)_103\(S_103\NP_98)_103)/NP_104>) (<T NP 0 1> (<T N 1 2> (<L N/N JJ JJ other N_120/N_120>) (<T N 1 2> (<L N/N NN NN brand N_113/N_113>) (<L N NNS NNS names N>) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_1542.7 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T S/S 1 2> (<L (S/S)/(S/S) JJ JJ Last (S_259/S_253)_259/(S_259/S_253)_259>) (<L S/S NN NN month S_245/S_245>) ) (<T S[dcl] 1 2> (<L , , , , ,>) (<T S[dcl] 1 2> (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP American N_235/N_235>) (<T N 1 2> (<L N/N NNP NNP Home N_228/N_228>) (<L N NNP NNP Products N>) ) ) ) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/S[dcl] VBD VBD said (S[dcl]\NP_88)/S[dcl]_89>) (<T S[dcl] 1 2> (<L NP PRP PRP it NP>) (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/(S[ng]\NP) VBD VBD was (S[dcl]\NP_98)/(S[ng]_99\NP_98:B)_99>) (<T S[ng]\NP 0 2> (<T S[ng]\NP 0 2> (<L (S[ng]\NP)/NP VBG VBG suspending (S[ng]\NP_106)/NP_107>) (<T NP 0 2> (<T NP 0 1> (<T N 1 2> (<L N NN NN production N>) (<T N[conj] 1 2> (<L conj CC CC and conj>) (<L N NN NN distribution N>) ) ) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN of (NP_122\NP_122)/NP_123>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT all NP[nb]_130/N_130>) (<L N CD CD 21 N>) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN of (NP_138\NP_138)/NP_139>) (<T NP 1 2> (<T NP[nb]/N 1 2> (<T NP 0 1> (<L N NNP NNP Quantum N>) ) (<L (NP[nb]/N)\NP POS POS 's (NP[nb]_162/N_162)\NP_163>) ) (<T N 1 2> (<L N/N JJ JJ generic N_155/N_155>) (<T N 1 2> (<L N/N NN NN drug N_148/N_148>) (<L N NNS NNS products N>) ) ) ) ) ) ) ) ) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP VBG VBG pending ((S_179\NP_174)_179\(S_179\NP_174)_179)/NP_180>) (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_187/N_187>) (<L N NN NN completion N>) ) (<T NP\NP 0 2> (<L (NP\NP)/NP IN IN of (NP_195\NP_195)/NP_196>) (<T NP 1 2> (<L NP[nb]/N DT DT an NP[nb]_217/N_217>) (<T N 1 2> (<L N/N JJ JJ exhaustive N_212/N_212>) (<T N 1 2> (<L N/N JJ JJ internal N_205/N_205>) (<L N NN NN audit N>) ) ) ) ) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_1542.8 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<L NP PRP PRP It NP>) (<T S[dcl]\NP 1 2> (<L (S\NP)/(S\NP) RB RB also (S_275\NP_270)_275/(S_275\NP_270)_275>) (<T S[dcl]\NP 1 2> (<L (S\NP)/(S\NP) RB RB temporarily (S_263\NP_258)_263/(S_263\NP_258)_263>) (<T S[dcl]\NP 0 2> (<T S[dcl]\NP 0 2> (<T S[dcl]\NP 0 2> (<L (S[dcl]\NP)/NP VBD VBD closed (S[dcl]\NP_161)/NP_162>) (<T NP 0 1> (<L N NNP NNP Quantum N>) ) ) (<L , , , , ,>) ) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/PP IN IN because ((S_180\NP_175)_180\(S_180\NP_175)_180)/PP_181>) (<T PP 0 2> (<L PP/NP IN IN of PP/NP_186>) (<T NP 0 2> (<T NP 0 2> (<T NP 0 2> (<T NP 0 2> (<T NP 0 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_200/N_200>) (<T N 1 2> (<L N/N JJ JJ internal N_195/N_195>) (<L N NN NN investigation N>) ) ) (<L , , , , ,>) ) (<L NP\NP RB RB as NP_209\NP_209>) ) (<L NP\NP RB RB well NP_216\NP_216>) ) (<L NP\NP IN IN as NP_223\NP_223>) ) (<T NP\NP 0 2> (<T (NP\NP)/N 1 2> (<T NP 1 2> (<L NP[nb]/N DT DT the NP[nb]_242/N_242>) (<L N NNP NNP FDA N>) ) (<L ((NP\NP)/N)\NP POS POS 's ((NP_233\NP_233)/N_234)\NP_235>) ) (<T N 1 2> (<L N/N JJ JJ ongoing N_251/N_251>) (<L N NN NN inquiry N>) ) ) ) ) ) ) ) ) ) (<L . . . . .>) ) 
ID=wsj_1542.9 PARSER=GOLD NUMPARSE=1
(<T S[dcl] 0 2> (<T S[dcl] 1 2> (<T S/S 0 2> (<L (S/S)/NP IN IN In (S_215/S_215)/NP_216>) (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP New N_253/N_253>) (<T N 1 2> (<L N/N NNP NNP York N_246/N_246>) (<T N 1 2> (<L N/N NNP NNP Stock N_239/N_239>) (<T N 1 2> (<L N/N NNP NNP Exchange N_232/N_232>) (<T N 1 2> (<L N/N JJ JJ composite N_225/N_225>) (<L N NN NN trading N>) ) ) ) ) ) ) ) (<T S[dcl] 1 2> (<L , , , , ,>) (<T S[dcl] 1 2> (<T NP 0 1> (<T N 1 2> (<L N/N NNP NNP American N_204/N_204>) (<T N 1 2> (<L N/N NNP NNP Home N_197/N_197>) (<L N NNP NNP Products N>) ) ) ) (<T S[dcl]\NP 0 2> (<T S[dcl]\NP 0 2> (<T S[dcl]\NP 0 2> (<L S[dcl]\NP VBD VBD rose S[dcl]\NP_114>) (<T (S\NP)\(S\NP) 1 2> (<L ((S\NP)\(S\NP))/((S\NP)\(S\NP)) CD CD 75 ((S_149\NP_141)_149\(S_142\NP_141)_142)_149/((S_149\NP_141)_149\(S_142\NP_141)_142)_149>) (<L (S\NP)\(S\NP) NNS NNS cents (S_126\NP_121)_126\(S_126\NP_121)_126>) ) ) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP TO TO to ((S_162\NP_157)_162\(S_162\NP_157)_162)/NP_163>) (<T NP 0 1> (<T N 0 2> (<L N/N[num] $ $ $ N/N[num]_168>) (<L N[num] CD CD 105 N[num]>) ) ) ) ) (<T (S\NP)\(S\NP) 0 2> (<L ((S\NP)\(S\NP))/NP IN IN on ((S_184\NP_179)_184\(S_184\NP_179)_184)/NP_185>) (<T NP 0 1> (<L N NNP NNP Friday N>) ) ) ) ) ) ) (<L . . . . .>) ) 
